PDF(Pubmed)
Abstract：
With the rapid development and adoption of novel anti-cancer therapeutics, physicians commonly encounter cancer patients on regimens with recently approved drugs for which information about rare or long-term side effects may not be available. In this case, we present a young woman with cholangiocarcinoma who was treated with the rearranged during transfection (RET)-selective tyrosine kinase inhibitor (TKI), pralsetinib, and presented to the hospital with shortness of breath. We review her diagnosis of new-onset systolic dysfunction as a possible sequela of her TKI therapy to encourage ongoing efforts to enhance provider familiarity with the side effects of this important and increasingly prescribed drug class.
摘要：
随着新型抗癌疗法的迅速发展和采用,医生通常会遇到癌症患者使用最近批准的药物，这些药物可能无法获得有关罕见或长期副作用的信息。在这种情况下,我们介绍了一个年轻的女性胆管癌谁是用重排在转染（RET）-选择性酪氨酸激酶抑制剂（TKI），普雷替尼,出现在医院呼吸急促.我们回顾了她对新发收缩功能障碍的诊断，这可能是她的TKI治疗的后遗症，以鼓励正在进行的努力，以增强提供者对这种重要且越来越多的处方药的副作用的熟悉度。
